“…In active targeting, the surface of nanocarriers is modified to generate affinity with bioreceptors or cellular biomarkers, tissues or organs through ligand-receptor interactions [ 46 , 53 ]. Ligand-nanocarrier conjugation uses different coupling methodologies, including the formation of disulfide bonds, cross-linking, covalent coupling, ionic interactions, layer-by-layer assembly, among other strategies [ 54 ]. Coating the nanocarriers with targeting ligands such as peptides, antibodies, lectins, sugars, folate- and mannose-receptors, among others, drive them to the site of action, thereby increasing the concentration of the active principle in the place and avoiding non-specific accumulations and the concomitant adverse effects [ 55 , 56 , 57 ].…”